APA

Strober B., Menter A., Leonardi C., Gordon K., Lambert J., Puig L., Photowala H., Longcore M., Zhan T. & Foley P. (20210514). Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. : Journal of the European Academy of Dermatology and Venereology : JEADV.

Chicago

Strober B, Menter A, Leonardi C, Gordon K, Lambert J, Puig L, Photowala H, Longcore M, Zhan T and Foley P. 20210514. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. : Journal of the European Academy of Dermatology and Venereology : JEADV.

Harvard

Strober B., Menter A., Leonardi C., Gordon K., Lambert J., Puig L., Photowala H., Longcore M., Zhan T. and Foley P. (20210514). Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. : Journal of the European Academy of Dermatology and Venereology : JEADV.

MLA

Strober B, Menter A, Leonardi C, Gordon K, Lambert J, Puig L, Photowala H, Longcore M, Zhan T and Foley P. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. : Journal of the European Academy of Dermatology and Venereology : JEADV. 20210514.